Cost-effectiveness of particle therapy: Current evidence and future needs

被引:43
作者
Pijls-Johannesma, Madelon [1 ]
Pommier, Pascal [2 ]
Lievens, Yolande [3 ]
机构
[1] Univ Med Ctr, Maastricht Radiat Oncol MAASTRO Clin, NL-6229 ET Maastricht, Netherlands
[2] Canc Ctr Leon Berard, Dept Radiat Oncol, Lyon, France
[3] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
关键词
Particles; Hadron; Ion; Proton; Radiotherapy; Cost-effectiveness; Reimbursement;
D O I
10.1016/j.radonc.2008.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Questions are being raised regarding the cost of particle therapy (PT), and with them criticism that PT is too expensive to allow the expected gain in effectiveness. This paper aims to get more insight in the cost and cost-effectiveness of particle therapy and to discuss a future strategy that allows for critical assessment of this health technology. Material and methods: A systematic literature review based on an earlier published comprehensive review was performed and updated until June 1st 2008. Besides, current business plans of PT projects were examined. Additionally, results retrieved from a cost-simulation tool developed under auspice of the ENLIGHT were discussed. Results: The current literature on cost-effectiveness of PT is scarce, non-comparable, and largely not performed according to standard health technology assessment criteria. Besides, different perspectives for cost evaluations have been used, making it difficult to compare and to determine the relative impact in terms of costs for this new treatment modality. Conclusions: Evidence on the cost-effectiveness of PT is scarce. Adequate reimbursement is necessary to support such innovative yet costly treatments. For now, model-based economic evaluations performed at least from a health care perspective may help us to gain evidence-based insight into cost-effectiveness. (c) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 89 (2008) 127-134.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [41] Cost-Effectiveness of Proton Beam Therapy for Intraocular Melanoma
    Moriarty, James P.
    Borah, Bijan J.
    Foote, Robert L.
    Pulido, Jose S.
    Shah, Nilay D.
    PLOS ONE, 2015, 10 (05):
  • [42] Cost-effectiveness analysis of burning mouth syndrome therapy
    Hens, Manuel J.
    Alonso-Ferreira, Veronica
    Villaverde-Hueso, Ana
    Abaitua, Ignacio
    Posada de la Paz, Manuel
    COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 2012, 40 (02) : 185 - 192
  • [43] Health Economic Controversy and Cost-Effectiveness of Proton Therapy
    Lievens, Yolande
    Pijls-Johannesma, Madelon
    SEMINARS IN RADIATION ONCOLOGY, 2013, 23 (02) : 134 - 141
  • [44] Cognitive remediation therapy in schizophrenia: Cost-effectiveness analysis
    Patel, Anita
    Knapp, Martin
    Romeo, Renee
    Reeder, Clare
    Matthiasson, Pall
    Everitt, Brian
    Wykes, Til
    SCHIZOPHRENIA RESEARCH, 2010, 120 (1-3) : 217 - 224
  • [45] Cost-effectiveness of Medical Versus Surgical Therapy for BPH
    Valentin Shabataev
    Ashraf Allahwala
    Dean S. Elterman
    Current Bladder Dysfunction Reports, 2019, 14 : 13 - 17
  • [46] Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
    Bourke, L.
    Kirkbride, P.
    Hooper, R.
    Rosario, A. J.
    Chico, T. J. A.
    Rosario, D. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 9 - 13
  • [47] Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan
    Hiroshima, Yuichi
    Kondo, Masahide
    Sawada, Takuya
    Hoshi, Shu-Ling
    Okubo, Reiko
    Iizumi, Takashi
    Numajiri, Haruko
    Okumura, Toshiyuki
    Sakurai, Hideyuki
    CANCER MEDICINE, 2023, 12 (20): : 20450 - 20458
  • [48] Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
    Chen, Zhaoyan
    Zhan, Mei
    Tian, Fangyuan
    Xu, Ting
    ONCOLOGY LETTERS, 2020, 19 (01) : 424 - 430
  • [49] Evidence-based medicine is affordable: The cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis
    Andrews, G
    Simonella, L
    Lapsley, H
    Sanderson, K
    March, L
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 671 - 680
  • [50] Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane
    Sendi, PP
    Briggs, AH
    HEALTH ECONOMICS, 2001, 10 (07) : 675 - 680